Net loss widened to $51 million as revenue from flagship product ZEJULA plummeted 39%.
Gross margins compressed as product revenue fell while cost of product revenue remained flat.
XACDURO revenue grew 667% YoY, signaling a potential new primary growth driver.
Maintained strong liquidity of $761M but carries $213.8M in short-term debt.
Zai Lab's first quarter of 2026 presents a stark contrast between deteriorating legacy revenue and accelerating new-product growth. The company is effectively racing against the clock: it must scale XACDURO and successfully launch its pipeline assets before the erosion of ZEJULA and the weight of looming milestone payments compromise its balance sheet. The massive reduction in operating cash burn is a positive signal of management's focus on efficiency, but the widening net loss suggests that operating leverage has not yet materialized. Investors are now weighing the risk of a 'value trap'—where legacy product declines outpace new growth—against the potential for a massive re-rating driven by the Zoci and VYVGART catalysts. The synthesis of this filing suggests a high-volatility period ahead, where the company's survival and growth will depend less on its current cash balance and more on its ability to execute on regulatory approvals and manufacturing scale-up in the coming twelve months.